Table 3.
Review of eight seven cases of resected subcutaneous metastasis from gastric cancer after curative gastrectomy
| Case | Author | Year | Age | Sex | Histologic type | Stage | Adjuvant chemotherapy | Time of recurrence after gastrectomy (months) | Prognosis after resection of subcutaneous metastasis (months) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fruh | 2005 | 60 | N/A | Adenocarcinoma | II | N/A | 24 | 90 | Alive |
| 2 | Karayiannakis | 2010 | 76 | M | por, sig | III | Irinotecan, L-OHP | 4 | 1 | Dead |
| 3 | Wang | 2014 | 68 | M | adenocarcinoma | I | None | 120 | 8 | Dead |
| 4 | Cesaretti | 2014 | 60 | M | por | III | Epirubicin, CDDP, 5-FU CDDP, capecitabine, trastuzumab | 72 | 40 | Alive |
| 5 | Morita | 2017 | 65 | F | tub1 | IIA | N/A | 60 | 18 | Alive |
| 6 | Koyama | 2019 | 89 | M | N/A | IV | S-1 | 72 | N/A | |
| 7 | Our case | 2020 | 82 | M | tub2 > por | IIIA | None | 71 | 7 | Alive |
M male, F female, N/A not available, por poorly differentiated adenocarcinoma, sig signet ring cell carcinoma, tub2 moderately differentiated adenocarcinoma, tub1 well-differentiated adenocarcinoma, L-OHP oxaliplatin, 5-FU 5-fluorouracil, CDDP cisplatin